Literature DB >> 719608

The regressing thin malignant melanoma: a distinctive lesion with metastatic potential.

M A Gromet, W L Epstein, M S Blois.   

Abstract

To validate the supposition that thin malignant melanomas (less than 0.76 mm thick) of ordinarily low risk but with areas of regression may paradoxically metastasize, we observed 121 thin malignant melanomas over a six year period. Of these, 23 displayed readily apparent areas of regression, of which five (21.7%) metastasized. The incidence of metastases in their 98 counterparts without regression was 2.0% (2/98). The difference between the two is statistically significant (p = less than .01). Of the entire group of the two is statistically significant (p = less than .01). Of the entire group of thin melanomas, those with regression represented 19.0% (23/121) yet accounted for a disproportionate 71.4% (5/7) of all metastases. We conclude that regression is a relatively poor prognostic sign, whose occurrence within an otherwise thin melanoma represents a significant caveat to the current histologic staging system that equates thinness with low risk. We thus submit that patients whose malignant melanomas display regression be followed rigorously for evidence of metastases irrespective of the tumor's actual measured thickness or level of invasion.

Entities:  

Mesh:

Year:  1978        PMID: 719608     DOI: 10.1002/1097-0142(197811)42:5<2282::aid-cncr2820420528>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  34 in total

1.  The significance of inflammation and regression in melanoma.

Authors:  M G Cook
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1992

Review 2.  Regressing thin cutaneous malignant melanomas (< or = 1.0 mm) are associated with angiogenesis.

Authors:  R L Barnhill; M A Levy
Journal:  Am J Pathol       Date:  1993-07       Impact factor: 4.307

3.  Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance.

Authors:  Phyu P Aung; Priyadharsini Nagarajan; Victor G Prieto
Journal:  Lab Invest       Date:  2017-02-27       Impact factor: 5.662

4.  Immune response in melanoma: an in-depth analysis of the primary tumor and corresponding sentinel lymph node.

Authors:  Michelle W Ma; Ratna C Medicherla; Meng Qian; Eleazar Vega-Saenz de Miera; Erica B Friedman; Russell S Berman; Richard L Shapiro; Anna C Pavlick; Patrick A Ott; Nina Bhardwaj; Yongzhao Shao; Iman Osman; Farbod Darvishian
Journal:  Mod Pathol       Date:  2012-03-16       Impact factor: 7.842

5.  [Regression in malignant melanoma. Definition, etiopathogenesis, morphology and differential diagnosis].

Authors:  B E Paredes
Journal:  Pathologe       Date:  2007-11       Impact factor: 1.011

6.  Expression of transforming growth factor-beta 2 in malignant melanoma correlates with the depth of tumor invasion. Implications for tumor progression.

Authors:  J A Reed; N S McNutt; V G Prieto; A P Albino
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

7.  Thin (less than or equal to 1 mm) melanomas of the extremities are biologically favorable lesions not influenced by regression.

Authors:  H J Wanebo; P H Cooper; R W Hagar
Journal:  Ann Surg       Date:  1985-04       Impact factor: 12.969

8.  Local and in-transit metastases following definitive excision for primary cutaneous malignant melanoma.

Authors:  D F Roses; M N Harris; D Rigel; Z Carrey; R Friedman; A W Kopf
Journal:  Ann Surg       Date:  1983-07       Impact factor: 12.969

9.  Histopathology report of cutaneous melanoma and sentinel lymph node in Europe: a web-based survey by the Dermatopathology Working Group of the European Society of Pathology.

Authors:  Anna Batistatou; Martin G Cook; Daniela Massi
Journal:  Virchows Arch       Date:  2009-04-08       Impact factor: 4.064

10.  Prognostic value of tumour thickness in cutaneous malignant melanoma.

Authors:  I Jeffrey; P Royston; C Sowter; G Slavin; A Price; A Pomerance; S Goolamali; D Pinto
Journal:  J Clin Pathol       Date:  1983-01       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.